We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+3.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$751M
AUM Growth
-$32.5M
Cap. Flow
+$2.11M
Cap. Flow %
0.28%
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$22.1M
2
SYK icon
Stryker
SYK
+$18.4M
3
VRDN icon
Viridian Therapeutics
VRDN
+$14.4M
4
MCK icon
McKesson
MCK
+$12.9M
5
UNH icon
UnitedHealth
UNH
+$11.4M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.8M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$16.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.7M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
UTHR icon
United Therapeutics
UTHR
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NARI
51
DELISTED
Inari Medical, Inc. Common Stock
NARI
$3.94M 0.53%
77,223
+32,922
+74% +$1.62M
URGN icon
52
UroGen Pharma
URGN
$2.39B
$3.94M 0.52%
369,861
+22,320
+6% +$267K
APGE icon
53
Apogee Therapeutics
APGE
$10.2B
$3.85M 0.51%
+85,000
New +$4.33M
PHLT
54
DELISTED
Performant Healthcare Inc
PHLT
$3.8M 0.51%
1,257,805
-183,033
-13% -$629K
ETON icon
55
Eton Pharmaceutcials
ETON
$1.14B
$3.69M 0.49%
276,890
+16,664
+6% +$169K
ACLX
56
DELISTED
Arcellx
ACLX
$3.41M 0.45%
44,492
-22,000
-33% -$1.9M
SLN
57
Silence Therapeutics
SLN
$641M
$3.38M 0.45%
491,080
-6,790
-1% -$87.6K
ICLR icon
58
Icon
ICLR
$12.9B
$3.33M 0.44%
15,874
-10,338
-39% -$2.41M
STRO icon
59
Sutro Biopharma
STRO
$353M
$3.18M 0.42%
172,793
+1,180
+0.7% +$36K
MBX
60
MBX Biosciences
MBX
$3.23B
$3.13M 0.42%
+170,000
New +$3.62M
SIBN icon
61
SI-BONE Inc
SIBN
$852M
$3.04M 0.4%
216,600
+31,284
+17% +$421K
MLTX icon
62
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.94M 0.39%
54,294
-48,519
-47% -$2.48M
DVAX
63
DELISTED
Dynavax Technologies
DVAX
$2.82M 0.38%
220,980
+1,529
+0.7% +$18.5K
CRNX icon
64
Crinetics Pharmaceuticals
CRNX
$8.96B
$2.61M 0.35%
51,133
-26,490
-34% -$1.48M
INSM icon
65
Insmed
INSM
$28.9B
$2.46M 0.33%
35,668
+235
+0.7% +$16.9K
BFLY icon
66
Butterfly Network
BFLY
$2.52B
$2.34M 0.31%
+750,000
New +$1.95M
NSPR icon
67
InspireMD
NSPR
$40.3M
$2.25M 0.3%
854,716
+750,635
+721% +$2.02M
ATEC icon
68
Alphatec Holdings
ATEC
$1.49B
$2.1M 0.28%
228,334
-168,002
-42% -$1.34M
RLAY icon
69
Relay Therapeutics
RLAY
$4.4B
$2.06M 0.27%
+500,548
New +$2.72M
ARVN icon
70
Arvinas
ARVN
$580M
$2.05M 0.27%
106,871
+10,688
+11% +$260K
LFST icon
71
Lifestance Health
LFST
$4.67B
$2.04M 0.27%
277,471
-172,529
-38% -$1.24M
XERS icon
72
Xeris Biopharma Holdings
XERS
$1.55B
$1.96M 0.26%
578,511
+476,118
+465% +$1.53M
NAMS icon
73
NewAmsterdam Pharma
NAMS
$3.33B
$1.96M 0.26%
76,116
-29,218
-28% -$621K
MRUS
74
DELISTED
Merus
MRUS
$1.92M 0.26%
45,680
+331
+0.7% +$15.9K
MRVI icon
75
Maravai LifeSciences
MRVI
$861M
$1.91M 0.25%
+350,000
New +$2.25M
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Parkman Healthcare Partners held 104 positions worth $751M, down 4.2% from $783M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners's Q4 2024 filing shows 11 new, 46 increased, 31 reduced and 15 closed positions. Its largest new stake was McKesson: 23,000 shares worth $13.1M. The largest sale was Teleflex, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2024 buy was McKesson: 23,000 shares worth $13.1M.
  • Parkman Healthcare Partners added most to Gilead Sciences in Q4 2024, an estimated $22.1M increase.
  • Parkman Healthcare Partners's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $10.1M.
  • Parkman Healthcare Partners fully exited Teleflex in Q4 2024, selling an estimated $23.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $751M portfolio in Q4 2024.
  • Parkman Healthcare Partners opened 11 new positions and closed 15 in Q4 2024.
  • Parkman Healthcare Partners's portfolio value fell 4.2% quarter-over-quarter to $751M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.